Kaleli Muhammed Fatih, Sahin Ahmet T, Alsancak Yakup
Cardiology, Faculty of Medicine, Necmettin Erbakan University, Konya, TUR.
Cardiology, Beyhekim Training and Research Hospital, Konya, TUR.
Cureus. 2024 Dec 1;16(12):e74926. doi: 10.7759/cureus.74926. eCollection 2024 Dec.
Acute pulmonary embolism (APE) is a serious cardiovascular condition characterized by high rates of morbidity and mortality, with inflammation playing a significant role in the severity of the disease and patient outcomes. This study aimed to evaluate the effects of thrombolytic therapy on inflammatory markers in patients diagnosed with APE.
The study was conducted retrospectively on 138 individuals, 69 with pulmonary embolism and 69 without pulmonary embolism (control), who were admitted to Necmettin Erbakan University between January 2019 and April 2023. Demographic information, C-reactive protein (CRP), white blood cells (WBC), neutrophils, platelets, systemic immune-inflammation index (SII), neutrophil-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), multi-inflammatory index (MII-1 and MII-2), hemoglobin, and lymphocyte-to-C-reactive protein ratio (LCR) levels of the cases were evaluated. The inflammatory markers were measured before and after thrombolytic therapy.
Levels of CRP, WBC, SII, NLR, and MII-1 were significantly increased in the pulmonary embolism group compared to the control group (p<0.05). In contrast, there was a notable decrease in hemoglobin, MII-2, and LCR levels (p<0.05). In the pulmonary embolism group, levels of CRP, WBC, neutrophils, lymphocytes, hemoglobin, SII, NLR, and MII-1 were significantly lower after thrombolytic treatment compared to their levels before the treatment (p<0.05). Conversely, the post-thrombolytic treatment group exhibited significantly higher levels of platelets, PLR, and LCR compared to the pre-thrombolytic treatment group (p<0.05).
The findings indicate that novel inflammatory markers, such as SII, NLR, and MII, are elevated in APE and tend to decrease following thrombolytic therapy. This suggests that these markers could be useful for monitoring treatment effectiveness and predicting patient outcomes. However, further research is necessary to confirm their clinical utility.
急性肺栓塞（APE）是一种严重的心血管疾病，其发病率和死亡率很高，炎症在疾病的严重程度和患者预后中起着重要作用。本研究旨在评估溶栓治疗对诊断为APE的患者炎症标志物的影响。
本研究对2019年1月至2023年4月期间入住内克梅廷·埃尔巴坎大学的138名个体进行了回顾性研究，其中69例患有肺栓塞，69例未患肺栓塞（对照组）。评估了病例的人口统计学信息、C反应蛋白（CRP）、白细胞（WBC）、中性粒细胞、血小板、全身免疫炎症指数（SII）、中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、多炎症指数（MII-1和MII-2）、血红蛋白以及淋巴细胞与C反应蛋白比值（LCR）水平。在溶栓治疗前后测量炎症标志物。
与对照组相比，肺栓塞组的CRP、WBC、SII、NLR和MII-1水平显著升高（p<0.05）。相反，血红蛋白、MII-2和LCR水平显著降低（p<0.05）。在肺栓塞组中，溶栓治疗后CRP、WBC、中性粒细胞、淋巴细胞、血红蛋白、SII、NLR和MII-1的水平显著低于治疗前（p<0.05）。相反，溶栓治疗后组的血小板、PLR和LCR水平显著高于溶栓治疗前组（p<0.05）。
研究结果表明，SII、NLR和MII等新型炎症标志物在APE中升高，溶栓治疗后趋于降低。这表明这些标志物可能有助于监测治疗效果和预测患者预后。然而，需要进一步研究以证实它们的临床实用性。
